Oncolytics Biotech Inc T.ONC

Parsons not on ONCY board for licensing & biobuck deals

[Noteable]

ONCY didn't appoint James Parsons to the board to advise on licensing & biobuck deals.

https://www.oncolyticsbiotech.com/press-releases/detail/577/oncolytics-biotech-announces-voting-results-from-the

Furthermore, ONCY has recently begun describing peleareorep as an IMMUNE PLATFORM MOLECULE, which is consistent with the way that the molecular biologic agent works across a broad range of drug classes and indications in the treatment of multiple cancers.   

[fox7mf]

Agreed 100% that Parsons is there for one reason...to negotiate a buyout, most likely with Pfizer. Coffey just seems to consciously avoid any mention of the word buyout, obviously & appropriately playing his cards close to his chest. Anxious & exciting times ahead, as Onc may be acquired sometime in Q4 !

[Pelaimmune]

New to the Stockhouse board but am an !8 year buyer and believer in ONCY.  It has been awhile since I have been this optimistic.  I hold a large amount of shares and have never sold a single one.  I have read and listened to the recent report a half dozen times and there is a lot of optimism going forward.  It is like they are stating without "stating" that we have

[fox7mf]

Great first post Pelaimmume...agreed on all points. I think it's getting pretty safe to say you're going to be a wealthy genius...GLTA.

[Noteable]

Pfizer and BMS have both sought to employ what they have referred to as  a“String of Pearls” strategy which is an effort to accelerate discovery and development of new therapies by partnering with or acquiring small to medium size companies. Now that Big Pharma faces a looming patent cliff, and with over 1.7  Trillion dollars of Big Pharma money in the game looking for new innovative

[Noteable]

I guess RBC's Doug Miehem didn't read this post.

[Noteable]

Neither is Jonathan Rigby.  https://www.oncolyticsbiotech.com/press-releases/detail/581/oncolytics-biotech-appoints-jonathan-rigby-to-its-board